The effects of ramipril on sympathetic nervous system function in older patients with hypertension

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 4, 1999, Pages 420-427

  Lee, Cathy C ^a   Sidani, Mohamad A ^b   Hogikyan, Robert V ^b   Supiano, Mark A ^b  

^a CCGCB   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NORADRENALIN; RAMIPRIL;

ADULT; AGED; ALPHA ADRENERGIC STIMULATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; FOREARM BLOOD FLOW; HEMODYNAMICS; HUMAN; HYPERTENSION; MALE; NORADRENALIN BLOOD LEVEL; NORADRENALIN RELEASE; ORAL DRUG ADMINISTRATION; PLASMA CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYMPATHETIC FUNCTION;

EID: 0033010367     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70137-2     Document Type: Article

References (27)

1. 1. Beck LH. Aging changes in renal function. In: Hazzard WR, Bierman EL, Blass JP, Ettinger WH Jr, Halter JB, editors. Principles of geriatric medicine and gerontology. 3rd ed. New York: McGraw-Hill; 1994. p. 615-24.
2. 2. Supiano MA, Hogikyan RV, Sidani MA, Galechi AT, Krueger JL. Heightened sympathetic nervous system activity and α-adrenergic responsiveness in older hypertensive humans. Am J Physiol 1999;276:E519-29.
3. 3. Ball SG. The sympathetic nervous system and converting enzyme inhibition. J Cardiovasc Pharmacol 1989;13 (suppl 3):S17-21.
4. 4. Malik KU, Nasjletti A. Facilitation of adrenergic transmission by locally generated angiotensin II in rat mesenteric arteries. Circ Res 1976;38:26-30.
5. 5. Clough D, Collis M, Conway J, Halton R, Keddie J. Interaction of angiotensin-converting enzyme inhibitors with the function of the sympathetic nervous system. Am J Cardiol 1982;49:1410-4.
6. 6. Noll G. Differential effects of captopril and nitrates on muscle sympathetic nerve activity in volunteers. Circulation 1997;95:2286-92.
7. 7. Prats MV, Serra MM, Artero JB, Benito GM, Escuder PT, Nicolas JMM. Quinapril ACE-inhibition effects on adrenergic parameters in moderate essential hypertension. Kidney Int 1996;49:(suppl 55):S104-6.
8. 8. Giannattasio C, Cattaneo BM, Omboni S, Seravalle G, Bolla G, Turulo L, et al. Sympathomoderating influence of benazepril in essential hypertension. J Hypertens 1992;10:373-8.
9. 9. Prinz PN, Halter JB, Benedetti C, Raskind M. Circadian variation of plasma catecholamines in young and old men: relation to rapid eye movement and slow wave sleep. J Clin Endocrinol Metab 1979;49:300-4.
10. 10. Panza JA, Epstein SE, Quyyumi AA. Circadian variation in vascular tone and its relation to α-sympathetic vasoconstrictor activity. N Engl J Med 1991;325:986-90.
11. 11. Lukaski HC, Bolonchuk WW, Hall CB, Siders W. Validation of tetrapolar bioelectrical impedance method to assess human body composition. J Appl Physiol 1986;60:1327-32.
12. 12. Hogikyan RV, Supiano MA. Homologous upregulation of human arterial α-adrenergic responses by guanadrel. J Clin Invest 1993;256:1429-35.
13. 13. Hogikyan RV, Supiano MA. Arterial α-adrenergic responsiveness is decreased and sympathetic nervous system activity is increased in older human. Am J Physiol 1994; 266:E717-24.
14. 2-adrenergic receptor density is decreased in older humans. J Gerontol 1993;48:B173-9.
15. 2-adrenergic receptors in young and elderly humans. Am J Physiol 1989;256:E339-44.
16. 2-adrenergic receptors in purified membranes from human platelets. Mol Pharmol 1985;28:475-86.
17. 2-adrenergic receptor. Mol Pharmacol 1988;34;814-22.
18. 18. Evans MI, Halter JB, Porte D. Comparisons of double-and single-isotope enzymatic derivative methods for measuring catecholamines in human plasma. Clin Chem 1978;24:567-70.
19. 19. Linares OA, Jacquez JA, Zech LA, Smith MJ, Sanfield JA, Morrow LA, et al. Norepinephrine metabolism in humans. J Clin Invest 1987;80:1332-41.
20. 20. Morrow LA, Linares OA, Hill TJ, Sanfield JA, Supiano MA, Rosen SG, et al. Age differences in the plasma clearance mechanisms for epinephrine and norepinephrine in humans. J Endocrinol Metab 1987;65:508-11.
21. 2-adrenoceptor density during long-term antihypertensive therapy with nitrendipine and captopril. J Cardiovasc Pharmacol 1994;24:429-33.
22. 22. Becker RHA, Struthers AD, Brown MJ. Effect of captopril on changes in plasma noradrenaline induced by sodium nitroprusside. Br J Clin Pharmacol 1986;22:409-13.
23. 23. Nicholls MG, Espiner EA, Miles KD, Zweifler AJ, Julius S. Evidence against an interaction of angiotensin II with the sympathetic nervous system in man. Clin Endocrinol 1981;15:423-30.
24. 24. Millar JA, Derkx FHM, McLean K, Reid JL. Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521. Br J Clin Pharmacol 1982;14: 347-55.
25. 25. Clementi WA, Durst NL, McNay JL, Keeton TK. Captopril modifies the hemodynamic and neuroendocrine responses to sodium nitroprusside in hypertensive patients. Hypertension 1986;8:229-37.
26. 26. Philipp T, Sharma AM, Thiede H, Kribben A. Sympathetic nervous activity and noradrenaline reactivity during angiotensin converting enzyme inhibition. Am J Cardiol 1987;59:55D-9D.
27. 27. Michel MC, Brodde O, Insel PA. Peripheral adrenergic receptors in hypertension. Hypertension 1990;16:107-20.